Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Blood (2023) 142 (Supplement 1): 5946.

https://doi.org/10.1182/blood-2023-184344

Published: 2023

Journal Articles

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles

Blood (2023) 142 (Supplement 1): 389.

https://doi.org/10.1182/blood-2023-182376

Published: 2023

Journal Articles

Genomic Profiles and Associated Survival Prognosticators in Black Patients with Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 837.

https://doi.org/10.1182/blood-2023-181876

Published: 2023

Journal Articles

I-DATA Study: Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-Targeted/IDH-Targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated Adult AML Patients Not Candidates for Intensive Induction Therapy

Michael P Ozga, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Jill Buss, Andrea Laganson, Ethan Hamp, Yazan F. Madanat, Daniel A. Pollyea, Eytan M. Stein, Joshua F. Zeidner, Elaine R Mardis, Ann-Kathrin Eisfeld, Alice Mims

Blood (2023) 142 (Supplement 1): 1534.

https://doi.org/10.1182/blood-2023-187060

Published: 2023

Journal Articles

Clinical and Prognostic Implications of WT1 Mutations in De Novo and Relapsed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 959.

https://doi.org/10.1182/blood-2023-188319

Published: 2023

Journal Articles

Patient-Associated Survival Modulators in Adolescent and Young Adult (AYA) Patients (Pts) with Acute Myeloid Leukemia (AML)

Andrea Laganson, Victoria Klein, Deedra Nicolet, Aadarsh Teli, Krzysztof Mrózek, Jacob Wareti, Michael C Walker, Christopher Manring, James L Fisher, Electra D Paskett, Elizabeth Ghias, Alice Mims, Jesse J Plascak, Ann-Kathrin Eisfeld, Jill Buss

Blood (2023) 142 (Supplement 1): 2423.

https://doi.org/10.1182/blood-2023-186423

Published: 2023

Journal Articles

Ubtf- Tandem Duplications Are Recurrent Somatic Genetic Events in Adult AML and Associate with Additional Structural Variants and a Distinct Gene Expression Profile (Alliance)

Blood (2023) 142 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2023-186722

Published: 2023

Journal Articles

A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): Impact Study

Uma M. Borate, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Ann-Kathrin Eisfeld, Bethany L Mundy-Bosse

Blood (2023) 142 (Supplement 1): 1327.

https://doi.org/10.1182/blood-2023-189949

Published: 2023

Journal Articles

The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 292.

https://doi.org/10.1182/blood-2023-182967

Published: 2023

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Blood (2023) 142 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2023-185135

Published: 2023

Journal Articles

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients

Richard J Marrero, Deedra Nicolet, Vivek M. Shastri, Krzysztof Mrózek, Christopher J. Walker, William Blum, Bayard L Powell, Jonathan E Kolitz, Joseph O Moore, Geoffrey L Uy, Wendy Stock, Andrew J Carroll, John C. Byrd, Ann-Kathrin Eisfeld, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2023-187361

Published: 2023

Journal Articles

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2023-174059

Published: 2023

Journal Articles

The Ancestry-Related Landscape of Long Non-Coding RNAs (LncRNAs) in Acute Myeloid Leukemia (AML) and Its Impact on Patient (Pt) Survival

Blood (2023) 142 (Supplement 1): 722.

https://doi.org/10.1182/blood-2023-185030

Published: 2023

Journal Articles

Deconvoluting Clonal and Cellular Architecture in IDH -Mutant Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1591.

https://doi.org/10.1182/blood-2023-186322

Published: 2023

Journal Articles

Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML)

Vanessa E. Kennedy, Cheryl A C Peretz, Andrew Koh, Elaine Tran, Dalia Dhingra, Saurabh Gulati, Adam Sciambi, Olga Sala-Torra, Lan Beppu, Aaron C. Logan, Alexander Perl, Wendy Stock, Geoffrey L Uy, Ann-Kathrin Eisfeld, Jerald P. Radich, Catherine C. Smith

Blood (2023) 142 (Supplement 1): 4334.

https://doi.org/10.1182/blood-2023-182454

Published: 2023

Journal Articles

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Blood (2023) 142 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2023-188892

Published: 2023

Journal Articles

A Phase II Study of Clinical Efficacy of Venetoclax in Combination with Azacitidine in Patients with Therapy Related Myelodysplastic Syndrome (t-MDS)

Uma M. Borate, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Kristin L Koenig, Ann-Kathrin Eisfeld, Yazan F. Madanat

Blood (2023) 142 (Supplement 1): 6504.

https://doi.org/10.1182/blood-2023-190082

Published: 2023

Journal Articles

Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010)

Kellie J. Archer, Han Fu, Krzysztof Mrózek, Deedra Nicolet, Jessica Kohlschmidt, Alice S. Mims, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Eisfeld

Blood (2022) 140 (Supplement 1): 1913–1914.

https://doi.org/10.1182/blood-2022-166477

Published: 2022

Journal Articles

Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study

Jonathan Hyak, Deedra Nicolet, Jessica Kohlschmidt, Kellie J. Archer, James S. Blachly, Karilyn T. Larkin, Bayard L. Powell, Jonathan E. Kolitz, Maria R. Baer, William G. Blum, Geoffrey L. Uy, Wendy Stock, Richard M. Stone, John C. Byrd, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Alice S. Mims

Blood (2022) 140 (Supplement 1): 1284–1285.

https://doi.org/10.1182/blood-2022-167210

Published: 2022

Journal Articles

Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]

Nuria Mencia Trinchant, Jessica Kohlschmidt, Alexandra Gomez-Arteaga, John C. Byrd, Wendy Stock, Krzysztof Mrózek, Andrew J. Carroll, Richard M. Stone, Eileen Pacheco, Adolfo Martinez Tovar, Irma Olarte Carrillo, Anel Garcia Laguna, Christian Ramos Peñafiel, Duane C Hassane, Ann-Kathrin Eisfeld, Monica L. Guzman

Blood (2022) 140 (Supplement 1): 11009–11010.

https://doi.org/10.1182/blood-2022-170326

Published: 2022

NARROW

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles

Genomic Profiles and Associated Survival Prognosticators in Black Patients with Acute Myeloid Leukemia

I-DATA Study: Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-Targeted/IDH-Targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated Adult AML Patients Not Candidates for Intensive Induction Therapy

Clinical and Prognostic Implications of WT1 Mutations in De Novo and Relapsed Acute Myeloid Leukemia

Patient-Associated Survival Modulators in Adolescent and Young Adult (AYA) Patients (Pts) with Acute Myeloid Leukemia (AML)

Ubtf- Tandem Duplications Are Recurrent Somatic Genetic Events in Adult AML and Associate with Additional Structural Variants and a Distinct Gene Expression Profile (Alliance)

A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): Impact Study

The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

The Ancestry-Related Landscape of Long Non-Coding RNAs (LncRNAs) in Acute Myeloid Leukemia (AML) and Its Impact on Patient (Pt) Survival

Deconvoluting Clonal and Cellular Architecture in IDH -Mutant Acute Myeloid Leukemia

Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML)

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

A Phase II Study of Clinical Efficacy of Venetoclax in Combination with Azacitidine in Patients with Therapy Related Myelodysplastic Syndrome (t-MDS)

Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010)

Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study

Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only